Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis

Exclusion Criteria

• •Participants with non-plaque forms of psoriasis (erythrodermic, guttate, pustular or palmo-plantar psoriasis) or with drug-induced psoriasis.
• •Evidence of skin conditions other than psoriasis that would interfere with evaluation of the effect of the study medication.
• •Pregnant or lactating women or women planning to become pregnant during the study and / or within 28 days following the last dose of study medication.
• •Known allergies to excipients in ARQ-151 cream.
• •Participants who cannot discontinue the use of strong P-450 cytochrome inducers or inhibitors for two weeks prior to the baseline visit and during the study period.
• •Participants who are unwilling to refrain from using a tanning bed for 2 weeks before and during the study.
• •Participants who cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis.
• •Participants with a history of chronic alcohol or drug abuse in past 6 months.
• •History of and/or concurrent condition of serious hypersensitivity (anaphylactic shock or anaphylactoid reaction) to phosphodiesterase type 4 (PDE-4) inhibitors.
• •Current or a history of cancer within 5 years with the exception of fully excised skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.
• •Participants with active infection that requires oral or intravenous administration of antibiotics, antifungal or antiviral agents.
• •Participants who are unable to communicate, read or understand language, or who display another condition which makes them unsuitable for clinical study participation.